0001209191-18-038422.txt : 20180618
0001209191-18-038422.hdr.sgml : 20180618
20180618191649
ACCESSION NUMBER: 0001209191-18-038422
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180614
FILED AS OF DATE: 20180618
DATE AS OF CHANGE: 20180618
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Popovits Kimberly J
CENTRAL INDEX KEY: 0001333482
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51541
FILM NUMBER: 18905790
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENOMIC HEALTH INC
CENTRAL INDEX KEY: 0001131324
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 770552594
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-556-9300
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-14
0
0001131324
GENOMIC HEALTH INC
GHDX
0001333482
Popovits Kimberly J
301 PENOBSCOT DR.
REDWOOD CITY
CA
94063
1
1
0
0
President and CEO
Common Stock
2018-06-04
5
G
0
E
100
0.00
D
59517
D
Common Stock
2018-06-14
4
M
0
10000
17.18
A
246157
I
Held by the Popovits 2010 Trust
Common Stock
2018-06-14
4
S
0
9600
48.8556
D
236557
I
Held by the Popovits 2010 Trust
Common Stock
2018-06-14
4
S
0
400
49.755
D
236157
I
Held by the Popovits 2010 Trust
Common Stock
12298
I
Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits
Common Stock
16825
I
Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee.
Employee Stock Option (right to buy)
17.18
2018-06-14
4
M
0
10000
0.00
D
2020-02-18
Common Stock
0
57900
D
Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2017.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $48.52 to $49.29.
Represents weighted average sale price. Actual sale prices ranged from $49.71 to $49.80.
The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.
/s/ Jason W. Radford, Attorney-in-fact
2018-06-18